David Tran is the president of LuTran, a pharmaceutical R&D company focused on developing novel drug molecules for viral and neurological diseases like HIV, Ebola, and Alzheimer's. As president, his responsibilities include managerial and technical support, intellectual property evaluation, candidate selection, development review, toxicology review, combination analysis, portfolio management, business planning, strategic planning, and investor diligence. LuTran's goal is to improve drug efficacy, pharmacokinetics, and safety profiles through two novel platform chemistries and medicinal chemistry efforts. They focus on designing medicines that offer significant improvements for targeted drug receptors.

1. As president of LuTran, David Tran discovers and develops novel molecules with more efficacious and
safer drug properties with a primary focus on viral and neurological diseases, including patients
immunocompromised with HIV, individuals stricken with the Ebola virus and patients with
Alzheimer’s.
David’s Core Capabilities:
■ Provide managerial and technical support to CSO, management team and SAB
■ Evaluate intellectual property and due diligence
■ Lead compound candidate selection
■ In vitro and in vivo development and review of novel molecules
■ Toxicological profile review of novel drug candidates
■ Combination drug product analysis
■ Portfolio management
■ Collaborate on business plans and develop financing presentations
■ Guide strategic planning
■ Conduct investor diligence
Continuous transformation is key to our innovative research. Our innovation is the result of our
passion, commitment and pushing the limits of our understanding by exploring new ideas to
accelerate the discovery, development and delivery of next–generation medications. We celebrate
curiosity and encourage our researchers to take chances in discovering novel solutions to increase
longevity and improve quality of life for millions of people around the world.
Drug development at LuTran includes advancing two novel platform chemistries by selectively
choosing lead compounds where significant improvements can be made in the properties of our drug
targets.

2. We focus our medicinal chemistry efforts by designing medicines where our chemistries can offer
significant improvement in efficacy, favorable pharmacokinetics and provide superior toxicological
profiles for our drug targets. Our chemistry improves binding affinity and intrinsic potency through
stronger hydrophobic synergies in the target receptor and increases duration of action by being
resistant to CYP metabolism and consequently improves bioavailability. In addition, our chemistry
can improve lipophilicity for better penetration and enhances safety through maximizing specific
hydrophobic interactions.
Our pharmaceutical research and development company is focused on the development and
commercialization of innovative therapies for the treatment of debilitating viral diseases, including
AIDS, Ebola hemorrhagic and Alzheimer’s disease. LuTran has built a portfolio of 10 programs for the
development of more efficacious drugs to prevent, cure and manage the complications of these
diseases.